CN Patent

CN120958007A — 4'-取代核苷逆转录酶抑制剂的前药

Assigned to Merck Sharp and Dohme BV · Expires 2025-11-14 · 1y expired

What this patent protects

本发明涉及化合物A的前药： 其为核苷逆转录酶易位抑制剂(NRTTI)且适用于抑制HIV逆转录酶。本发明还涉及这些化合物用于预防HIV感染、治疗HIV感染以及预防、治疗和延迟AIDS和/或AIDS相关综合症的发作或进展的用途。

USPTO Abstract

本发明涉及化合物A的前药： 其为核苷逆转录酶易位抑制剂(NRTTI)且适用于抑制HIV逆转录酶。本发明还涉及这些化合物用于预防HIV感染、治疗HIV感染以及预防、治疗和延迟AIDS和/或AIDS相关综合症的发作或进展的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN120958007A
Jurisdiction
CN
Classification
—
Expires
2025-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.